Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors

Clinical Colorectal Cancer

Volumn 10, Issue 4, 2011, Pages 298-309

  Gupta, Sameer ^a   Engstrom, Paul F ^a   Cohen, Steven J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Neuroendocrine tumors; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE; PANOBINOSTAT; PASIREOTIDE; PAZOPANIB; PLACEBO; RAF PROTEIN; RAS PROTEIN; ROMIDEPSIN; SOMATOMEDIN RECEPTOR; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; CARCINOID; DIARRHEA; FATIGUE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MYELOID LEUKEMIA; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SUDDEN DEATH; VOMITING;

EID: 84862937104     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.06.006     Document Type: Review

References (121)

1. S. Oberndorfer Karzinoide Tumoren des Dunndarms [in German] Frankf Z Pathol 1 1907 426 430
2. G. Kloppel, A. Perren, and P.U. Heitz The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification Ann N Y Acad Sci 1014 2004 13 27 (Pubitemid 38594787)
3. J.C. Yao, M. Hassan, and A. Phan One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
4. D. Grama, B. Eriksson, and H. Martensson Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes World J Surg 16 1992 632 639
5. K.O. Shebani, W.W. Souba, and D.M. Finkelstein Prognosis and survival in patients with gastrointestinal tract carcinoid tumors Ann Surg 229 1999 815 821 discussion 822-3
6. I.M. Modlin, K.D. Lye, and M. Kidd A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 2003 934 959 (Pubitemid 36173145)
7. E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr Relat Cancer 14 2007 221 232 (Pubitemid 47242624)
8. P. Rougier, and M. Ducreux Systemic chemotherapy of advanced digestive neuroendocrine tumours Ital J Gastroenterol Hepatol 31 suppl 2 1999 S202 S206
9. A. Chaudhry, K. Funa, and K. Oberg Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system Acta Oncol 32 1993 107 114 (Pubitemid 23188522)
10. A. Chaudhry, K. Oberg, A. Gobl, C.H. Heldin, and K. Funa Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system Anticancer Res 14 5B 1994 2085 2091 (abstract)
11. A. Chaudhry, V. Papanicolaou, K. Oberg, C.H. Heldin, and K. Funa Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system Cancer Res 52 1992 1006 1012
12. B. Terris, J.Y. Scoazec, and L. Rubbia Expression of vascular endothelial growth factor in digestive neuroendocrine tumours Histopathology 32 1998 133 138 (Pubitemid 28126179)
13. O. Nilsson, B. Wangberg, L. Kolby, G.S. Schultz, and H. Ahlman Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours Int J Cancer 60 1995 645 651
14. S. Krishnamurthy, and Y. Dayal Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids Am J Surg Pathol 21 1997 327 333 (Pubitemid 27120202)
15. C.W. Chiu, H. Nozawa, and D. Hanahan Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis J Clin Oncol 28 2010 4425 4433
16. L.L. Siu Small tumors, intermediate models, big hopes J Clin Oncol 28 2010 4407 4409
17. I.M. Modlin, S.F. Moss, D.C. Chung, R.T. Jensen, and E. Snyderwine Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors J Natl Cancer Inst 100 2008 1282 1289
18. D. Hanahan Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes Nature 315 1985 115 122 (Pubitemid 15064530)
19. H. Kim, Y. Nagano, I.S. Choi, J.A. White, J.C. Yao, and A. Rashid Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors Genes Chromosomes Cancer 47 2008 84 92 (Pubitemid 350191467)
20. I.S. Choi, M.R. Estecio, and Y. Nagano Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors) Mod Pathol 20 2007 802 810 (Pubitemid 46933452)
21. M.A. Kouvaraki, J.A. Ajani, and P. Hoff Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas J Clin Oncol 22 2004 4762 4771
22. J.C. Reubi, L.K. Kvols, and B. Waser Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas Cancer Res 50 1990 5969 5977 (Pubitemid 20331408)
23. L.K. Kvols, C.G. Moertel, M.J. O'Connell, A.J. Schutt, J. Rubin, and R.G. Hahn Treatment of the malignant carcinoid syndrome Evaluation of a long-acting somatostatin analogue N Engl J Med 315 1986 663 666 (Pubitemid 16055931)
24. M. Appetecchia, and R. Baldelli Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives J Exp Clin Cancer Res 29 2010 19
25. W.W. de Herder, and S.W. Lamberts Somatostatin and somatostatin analogues: diagnostic and therapeutic uses Curr Opin Oncol 14 2002 53 57 (Pubitemid 34072964)
26. W. Bauer, U. Briner, and W. Doepfner SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1982 1133 1140 (Pubitemid 13243115)
27. K. Oberg, L. Kvols, and M. Caplin Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Ann Oncol 15 2004 966 973 (Pubitemid 39004355)
28. T. Aparicio, M. Ducreux, and E. Baudin Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours Eur J Cancer 37 2001 1014 1019 (Pubitemid 32397687)
29. R. Arnold, C. Neuhaus, and R. Benning Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors World J Surg 17 1993 511 519 (Pubitemid 23228405)
30. L.K. Kvols Metastatic carcinoid tumors and the malignant carcinoid syndrome Ann N Y Acad Sci 733 1994 464 470
31. A. Rinke, H.H. Muller, and C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
32. L.J. Hofland, P.M. van Koetsveld, M. Waaijers, J. Zuyderwijk, and S.W. Lamberts Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells Endocrinology 134 1994 301 306
33. S. Faiss, U.F. Pape, and M. Bohmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumorsthe International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696 (Pubitemid 46606312)
34. Phase III Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour ClinicalTrials.gov [Web site] http://clinicaltrials.gov/ct2/show/NCT00353496 Accessed: September 27, 2010
35. L. Kvols, B. Wiedenmann, and K. Oberg Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study ASCO Gastrointestinal Cancers Symposium 2006 Abstract 171
36. R.K. Jain Molecular regulation of vessel maturation Nat Med 9 2003 685 693 (Pubitemid 36749217)
37. S. La Rosa, S. Uccella, G. Finzi, L. Albarello, F. Sessa, and C. Capella Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features Hum Pathol 34 2003 18 27 (Pubitemid 36160017)
38. G. Christofori, P. Naik, and D. Hanahan Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis Mol Endocrinol 9 1995 1760 1770
39. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803 (Pubitemid 37328914)
40. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
41. E. Missiaglia, I. Dalai, and S. Barbi Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2010 245 255
42. Avastin [package insert] 2009 Genentech, Inc. South San Francisco, CA
43. J.C. Yao, A. Phan, and P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 2008 1316 1323
44. Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients ClinicalTrials.gov [Web site] http://clinicaltrials.gov/ct2/show/NCT00569127?term=NCT00569127&rank=1 Accessed: June17, 2010
45. P.L. Kunz, T. Kuo, and J.M. Zahn A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors J Clin Oncol 28 suppl 15 2010 4104 [Abstract]
46. A.P. Venook, A.H. Ko, and M.A. Tempero Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors J Clin Oncol 26 suppl 15 2008 15545 [Abstract]
47. M.H. Kulke, K. Stuart, and C.C. Earle A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors J Clin Oncol 24 suppl 18 2006 4044 [Abstract]
48. E. Bajetta, L. Catena, and G. Procopio Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59 2007 637 642 (Pubitemid 46295128)
49. P.A. Cassier, T. Walter, and B. Eymard Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience Cancer 115 2009 3392 3399
50. F. Maire, P. Hammel, and S. Faivre Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors Neuroendocrinology 90 2009 67 72
51. M.H. Kulke, H.J. Lenz, and N.J. Meropol Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 2008 3403 3410
52. Sutent [package insert] 2010 Pfizer, Inc. New York, NY
53. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337 (Pubitemid 36109749)
54. S. Faivre, C. Delbaldo, and K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35 (Pubitemid 46630490)
55. E. Raymond, P. Niccoli, and Y. Bang Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) ASCO Gastrointestinal Cancers Symposium 2010 abstract 21
56. L. Liu, Y. Cao, and C. Chen Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858 (Pubitemid 46094197)
57. H. Chai, A.Z. Luo, P. Weerasinghe, and R.E. Brown Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line Int J Clin Exp Pathol 3 2010 408 415
58. Nexavar [package insert] 2009 Onyx Pharmaceuticals, Inc. and Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ
59. T.J. Hobday, J. Rubin, and K. Holen MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study J Clin Oncol 25 suppl 18 2007 4504
60. G. Sonpavde, and T.E. Hutson Pazopanib: a novel multitargeted tyrosine kinase inhibitor Curr Oncol Rep 9 2007 115 119 (Pubitemid 46332383)
61. Votrient [package insert] 2010 GlaxoSmithKline Research Triangle Park, NC
62. A. Phan, J. Yao, and D. Fogelman A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) J Clin Oncol 28 suppl 7 2010 [Abstract 4001]
63. K. Mross Inhibition des VEGF- Rezeptorsystems mit Tyrosinkinase- Inhibitoren Angiogenese-Inhibition in der Onkologie [in German] Pharm Unserer Zeit 37 2008 404 415
64. B. Lin, K. Podar, and D. Gupta The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Res 62 2002 5019 5026 (Pubitemid 34984429)
65. L.B. Anthony, M. Chester, and S. Michael Phase II open-label clinical trial of vatalanib (PTK787) in patients with progressive neuroendocrine cancer ASCO Gastrointestinal Cancers Symposium 2008 abstract 146
66. Gleevac [package insert] 2010 Novartis Pharmaceuticals Corporation East Hanover, NJ
67. J.C. Yao, J.X. Zhang, and A. Rashid Clinical and in vitro studies of imatinib in advanced carcinoid tumors Clin Cancer Res 13 2007 234 240 (Pubitemid 46121874)
68. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085 (Pubitemid 24139577)
69. Thalidomid [package insert] 2010 Celgene Corporation Summit, NJ
70. K.A. Varker, J. Campbell, and M.H. Shah Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors Cancer Chemother Pharmacol 61 2008 661 668
71. M.H. Kulke, K. Stuart, and P.C. Enzinger Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 2006 401 406 (Pubitemid 46630459)
72. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501 (Pubitemid 37328931)
73. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945 (Pubitemid 39071573)
74. M. Laplante, and D.M. Sabatini mTOR signaling at a glance J Cell Sci 122 2009 3589 3594
75. A. Moreno, A. Akcakanat, M.F. Munsell, A. Soni, J.C. Yao, and F. Meric-Bernstam Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors Endocr Relat Cancer 15 2008 257 266 (Pubitemid 351449744)
76. J.C. Yao, A.T. Phan, and D.Z. Chang Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 2008 4311 4318
77. J.C. Yao, C. Lombard-Bohas, and E. Baudin Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
78. M. Pavel, J.D. Hainsworth, and E. Baudin A randomized, double-blind, placebo-controlled, multicenter phase Iii trial of everolimus + octreotide LAR vs placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2) ESMO Annual Meeting, Late Breaking Abstract 8 2010
79. J.C. Yao, M.H. Shah, and T. Ito A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine tumors (PNET) (RADIANT-3) ESMO Annual Meeting, Late Breaking Abstract 9 2010
80. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154 (Pubitemid 44660065)
81. J.C. Yao, A.T. Phan, and D. Fogleman Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker J Clin Oncol 28 suppl 15 2010 4002 [Abstract]
82. G. von Wichert, P.M. Jehle, and A. Hoeflich Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells Cancer Res 60 2000 4573 4581 (Pubitemid 32103642)
83. M. Furukawa, M. Raffeld, and C. Mateo Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases Clin Cancer Res 11 2005 3233 3242 (Pubitemid 40627870)
84. D. Burtrum, Z. Zhu, and D. Lu A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 2003 8912 8921 (Pubitemid 38064071)
85. L.B. Anthony, P.J. Loehrer, and S. Leong Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma J Clin Oncol 28 suppl 7 2010 15s [Abstract]
86. D.L. Reidy, E. Hollywood, M. Segal, and L. Saltz A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs) J Clin Oncol 28 suppl 15 2010 4163 [Abstract]
87. K.E. O'Reilly, F. Rojo, and Q.B. She mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508 (Pubitemid 43259931)
88. S. Di Cosimo, J.C. Bendell, and A. Cervantes-Ruiperez A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors J Clin Oncol 28 suppl 15 2010 3008 [Abstract]
89. J. Baselga, and S.M. Swain Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 2009 463 475
90. M. Hopfner, A.P. Sutter, B. Gerst, M. Zeitz, and H. Scherubl A novel approach in the treatment of neuroendocrine gastrointestinal tumours Targeting the epidermal growth factor receptor by gefitinib (ZD1839) Br J Cancer 89 2003 1766 1775 (Pubitemid 37464152)
91. Iressa [package insert] 2009 AstraZeneca Pharmaceuticals Wilmington, DE
92. T.J. Hobday, K. Holen, and R. Donehower A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study J Clin Oncol 24 suppl 18 2006 2006 4043
93. Intron [package insert] 2001 Schering Corporation Kenilworth, NJ
94. Z. von Marschall, A. Scholz, and T. Cramer Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis J Natl Cancer Inst 95 2003 437 448 (Pubitemid 36432418)
95. R.K. Singh, M. Gutman, and C.D. Bucana Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas Proc Natl Acad Sci U S A 92 1995 4562 4566
96. K.M. Detjen, M. Welzel, and K. Farwig Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells Gastroenterology 118 2000 735 748 (Pubitemid 30171623)
97. K. Oberg, K. Funa, and G. Alm Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome N Engl J Med 309 1983 129 133 (Pubitemid 13069520)
98. K. Oberg The action of interferon alpha on human carcinoid tumours Semin Cancer Biol 3 1992 35 41
99. L. Dahan, F. Bonnetain, and P. Rougier Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr Relat Cancer 16 2009 1351 1361
100. W.D. Cress, and E. Seto Histone deacetylases, transcriptional control, and cancer J Cell Physiol 184 2000 1 16 (Pubitemid 30349623)
101. P. Gallinari, S. Di Marco, P. Jones, M. Pallaoro, and C. Steinkuhler HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res 17 2007 195 211 (Pubitemid 46438722)
102. V. Baradari, A. Huether, M. Hopfner, D. Schuppan, and H. Scherubl Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells Endocr Relat Cancer 13 2006 1237 1250 (Pubitemid 46212577)
103. D.Y. Greenblatt, A.M. Vaccaro, and R. Jaskula-Sztul Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells Oncologist 12 2007 942 951 (Pubitemid 47359136)
104. Istodax [package insert] 2009 Gloucester Pharmaceuticals Inc. Cambridge, MA City, State
105. M.H. Shah, P. Binkley, and K. Chan Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors Clin Cancer Res 12 2006 3997 4003 (Pubitemid 44078086)
106. J. Tan, S. Cang, Y. Ma, R.L. Petrillo, and D. Liu Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J Hematol Oncol 3 2010 5
107. A Phase II Trial of Panobinostat in Patients With Neuroendocrine Tumors ClinicalTrials.gov [Web site] http://www.clinicaltrials.gov/ct2/show/NCT00985946 Accessed: June 10, 2010. ClinicalTrials.gov Identifier: NCT00985946
108. J.A. Gollob, S. Wilhelm, C. Carter, and S.L. Kelley Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 2006 392 406 (Pubitemid 44142735)
109. M. Kunnimalaiyaan, and H. Chen The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17 2006 139 142
110. J.I. Park, C.J. Strock, D.W. Ball, and B.D. Nelkin The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway Mol Cell Biol 23 2003 543 554 (Pubitemid 36050548)
111. R.S. Sippel, and H. Chen Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation Surgery 132 2002 1035 1039 (Pubitemid 36026952)
112. J.J. Van Gompel, and H. Chen Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells Surgery 136 2004 1297 1302 (Pubitemid 39647548)
113. C.A. Hall-Jackson, P.A. Eyers, and P. Cohen Paradoxical activation of Raf by a novel Raf inhibitor Chem Biol 6 1999 559 568 (Pubitemid 29380770)
114. K. Cichowski, and P.A. Janne Drug discovery: inhibitors that activate Nature 464 2010 358 359
115. M. Kunnimalaiyaan, A.M. Vaccaro, M.A. Ndiaye, and H. Chen Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells Mol Cancer Ther 6 2007 1151 1158 (Pubitemid 46554586)
116. D. Yu, M. Greenblatt, H. Chen, and M. Kunnimalaiyaan Lithium inhibits carcinoid cell growth in vitro Am J Transl Res 2 2010 248 253
117. S.J. Lubner, H. Chen, and K. Holen A phase II clinical and biological study of lithium carbonate (Li) in patients with low-grade neuroendocrine tumors J Clin Oncol 27 suppl 15 2009 e15662 [Abstract]
118. V.M. Bolanos-Garcia Aurora kinases Int J Biochem Cell Biol 37 2005 1572 1577 (Pubitemid 40719637)
119. D. Benten, K. Fraedrich, and J. Schrader W1946 a novel small-molecule aurora kinase inhibitor with strong antiproliferative activity in human carcinoid cell lines Gastroenterology 134 suppl 1 2008 740 [Abstract]
120. I. Georgieva, D. Koychev, and Y. Wang ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines Neuroendocrinology 91 2010 121 130
121. I. Astsaturov, V. Ratushny, and A. Sukhanova Synthetic lethal screen of an EGFR-centered network to improve targeted therapies Sci Signal 3 2010 67 [Abstract]